220 related articles for article (PubMed ID: 29547059)
1. Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis.
Kim YI; Paeng JC; Park YS; Cheon GJ; Lee DS; Chung JK; Kang KW
AJR Am J Roentgenol; 2018 Jun; 210(6):1346-1351. PubMed ID: 29547059
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
Wang D; Zhang M; Gao X; Yu L
PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
[TBL] [Abstract][Full Text] [Related]
3. Primary metabolic tumor volume from 18F-FDG PET/CT associated with epidermal growth factor receptor mutation in lung adenocarcinoma patients.
Liao X; Cui Y; Chen X; Di L; Tong Z; Liu M; Wang R
Nucl Med Commun; 2020 Nov; 41(11):1210-1217. PubMed ID: 32815896
[TBL] [Abstract][Full Text] [Related]
4. [Semiquantitative parameters of
Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
[TBL] [Abstract][Full Text] [Related]
5. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
Yanarateş A; Yazici B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
[TBL] [Abstract][Full Text] [Related]
6. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
[No Abstract] [Full Text] [Related]
7. Predictive value of intratumor metabolic and heterogeneity parameters on [
Ni M; Wang S; Liu X; Shi Q; Zhu X; Zhang Y; Xie Q; Lv W
Jpn J Radiol; 2023 Feb; 41(2):209-218. PubMed ID: 36219311
[TBL] [Abstract][Full Text] [Related]
8. Relationship between
Bu L; Tu N; Wang K; Zhou Y; Xie X; Han X; Lin H; Feng H
Korean J Radiol; 2022 Jan; 23(1):112-123. PubMed ID: 34983098
[TBL] [Abstract][Full Text] [Related]
9. Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma.
Ho TY; Chou PC; Yang CT; Tsang NM; Yen TC
Clin Nucl Med; 2015 Jun; 40(6):e295-9. PubMed ID: 25783515
[TBL] [Abstract][Full Text] [Related]
10. (
Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of integrating total metabolic tumor volume and EGFR mutation status in patients with lung adenocarcinoma.
Jiang M; Guo X; Chen P; Zhang X; Gao Q; Zhang J; Zheng J
PeerJ; 2024; 12():e16807. PubMed ID: 38250731
[TBL] [Abstract][Full Text] [Related]
12. Correlation between EGFR mutation status and F
Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
[TBL] [Abstract][Full Text] [Related]
13. Correlations Study Between
Yang B; Wang QG; Lu M; Ge Y; Zheng YJ; Zhu H; Lu G
Front Oncol; 2019; 9():589. PubMed ID: 31380265
[No Abstract] [Full Text] [Related]
14. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
[TBL] [Abstract][Full Text] [Related]
15. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
Kaira K; Shimizu K; Kitahara S; Yajima T; Atsumi J; Kosaka T; Ohtaki Y; Higuchi T; Oyama T; Asao T; Mogi A
Eur J Cancer; 2018 Sep; 101():181-190. PubMed ID: 30077123
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging.
Chirindel A; Alluri KC; Chaudhry MA; Wahl RL; Pawlik TM; Herman JM; Subramaniam RM
AJR Am J Roentgenol; 2015 May; 204(5):1093-9. PubMed ID: 25905947
[TBL] [Abstract][Full Text] [Related]
17. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity index evaluated by slope of linear regression on
Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1995-2003. PubMed ID: 28634684
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of multiple metabolic and heterogeneity parameters of
Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
[TBL] [Abstract][Full Text] [Related]
20. FDG PET texture indices as imaging biomarkers for epidermal growth factor receptor mutation status in lung adenocarcinoma.
Ishimura M; Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Murota M; Kanaji N; Nishiyama Y
Sci Rep; 2023 Apr; 13(1):6742. PubMed ID: 37185611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
